RB1 Mutations Linked to Worse Outcomes in Prostate Cancer Patients, Study Finds

RB1 Mutations Linked to Worse Outcomes in Prostate Cancer Patients, Study Finds
Men whose tumors contain mutations in the retinoblastoma (RB1) gene have higher risks of prostate cancer relapse and mortality while receiving first-line conventional anti-cancer therapies, a study says. According to researchers, genetic screenings aimed at identifying patients whose tumors may contain such genetic alterations may be crucial to pinpoint   those in need of intensive treatment. The study with those findings, "Genomic correlates of clinical outcome in advanced prostate cancer," was published in PNAS. Recent studies have shown that both primary and metastatic (spreading) forms of prostate cancer are highly variable from a genomic standpoint. However, the impact of this tumor genetic variability on patients' clinical outcomes is still poorly understood. Researchers from The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust in collaboration with colleagues from the U.S. and other European countries, set out to investigate possible relationships between specific genetic mutations found in tumors of patients with advanced forms of prostate cancer and their long-term clinical outcomes. To this end, they performed a full genetic characterization of 444 tumors samples collected from 429 patients who had been diagnosed with metastatic
Subscribe or to access all post and page content.